Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Flexion Therapeutics (FLXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 935,121
  • Shares Outstanding, K 37,540
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,890 K
  • 36-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.67 +14.98%
on 11/14/17
27.49 -9.39%
on 11/27/17
+0.92 (+3.83%)
since 11/10/17
3-Month
19.06 +30.69%
on 10/26/17
32.25 -22.76%
on 10/06/17
+0.91 (+3.79%)
since 09/11/17
52-Week
16.51 +50.88%
on 06/15/17
32.25 -22.76%
on 10/06/17
+5.36 (+27.42%)
since 12/09/16

Most Recent Stories

More News
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company's Vice President of Medical Affairs,...

FLXN : 24.91 (-2.20%)
Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA(TM) (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics (PK) and safety of concurrent injections of ZILRETTA (triamcinolone...

FLXN : 24.91 (-2.20%)
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate...

FLXN : 24.91 (-2.20%)
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,500 shares of common stock. The Compensation Committee of the...

FLXN : 24.91 (-2.20%)
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market

Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.

PETS : 42.69 (-0.42%)
MYGN : 32.48 (-3.73%)
LMNX : 20.27 (-1.31%)
FLXN : 24.91 (-2.20%)
Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate...

FLXN : 24.91 (-2.20%)
Today's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical

NEW YORK, NY / ACCESSWIRE / November 27, 2017 / Shares of Flexion were on a rampage this past Friday, closing the day up over 12%. It was last week that the company announced the full commercial launch...

TEVA : 16.44 (+2.37%)
FLXN : 24.91 (-2.20%)
Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA(TM) (triamcinolone acetonide extended-release injectable suspension)

-- Recently approved, non-opioid therapy now available for the management of osteoarthritis knee pain

FLXN : 24.91 (-2.20%)
Flexion Therapeutics Named Top Place to Work for 2017 by Theâ?? â??Bostonâ?? â??Globeâ??

-- Annual survey recognizes and honors the best employers in Massachusetts

FLXN : 24.91 (-2.20%)
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com shifts focus on Catalyst...

SUPN : 37.95 (-0.52%)
AGN : 172.76 (+2.96%)
CPRX : 4.20 (+5.00%)
FLXN : 24.91 (-2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United...

See More

Key Turning Points

2nd Resistance Point 26.39
1st Resistance Point 25.65
Last Price 24.91
1st Support Level 24.49
2nd Support Level 24.07

See More

52-Week High 32.25
Fibonacci 61.8% 26.24
Last Price 24.91
Fibonacci 50% 24.38
Fibonacci 38.2% 22.52
52-Week Low 16.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.